Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Up 320.0% in June

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totaling 94,847 shares, a growth of 320.0% from the June 15th total of 22,583 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 483,454 shares, the days-to-cover ratio is currently 0.2 days.

Oncotelic Therapeutics Stock Down 5.4%

Shares of OTCMKTS OTLC traded down $0.00 during trading hours on Friday, hitting $0.04. 74,204 shares of the stock were exchanged, compared to its average volume of 277,382. The firm has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.05. The company has a market cap of $17.67 million, a PE ratio of 0.07 and a beta of -0.27. The company has a quick ratio of 0.11, a current ratio of 0.11 and a debt-to-equity ratio of 0.01. Oncotelic Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last posted its quarterly earnings data on Wednesday, April 15th. The company reported $0.59 earnings per share for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.